Silica exposure and systemic vasculitis. by Mulloy, Karen B
Case Presentation
During a medical screening program for 
former Department of Energy (DOE) workers
by the Johns Hopkins University Former Los
Alamos National Laboratory (LANL) Workers
Program (Espanola, NM) a 63-year-old white
male expressed concern that his diagnoses of
microscopic polyangiitis, systemic necrotizing
vasculitis, leukocytoclastic vasculitis, pul-
monary interstitial fibrosis, and glomerulo-
nephritis were related to silica exposure. He
had applied for compensation under the fed-
eral Energy Employees Occupational Illness
Compensation Program (EEOICP). He was
referred to the University of New Mexico’s
Program in Occupational and Environmental
Health.
Before 1988 the patient’s medical history
included a) irritable bowel syndrome and hypo-
glycemia; b) seasonal allergies with chronic
polyposis and deviated nasal septum with mod-
erate to severe obstruction; c) eustachian tube
rupture with corrective septoplasty and bilateral
turbinoplasties; d) pneumonia and pleural effu-
sions; and e) hypertension.
In 1988 the patient developed migratory
joint pain that progressed in severity, and by
1989 he had difﬁculty walking. Short course
prednisone treatment provided relief. In 1989,
a painful macular erythematous lesion devel-
oped on the patient’s chest; a skin biopsy diag-
nosed leukocytoclastic vasculitis. In spring
1992, he was referred to the Mayo Clinic
(Scottsdale, AZ) for pulmonary and renal
workup for gross hematuria and dyspnea.
Results of laboratory tests are presented in
Table 1. Renal biopsy showed proliferative
(crescentric) and necrotizing glomerulo-
nephritis; treatment with prednisone and
cyclophosamide placed patient in prompt
remission (Table 1). In late 1992 the patient
developed acute shortness of breath, and
spirometry, lung scan, and bronchoscopy with
biopsy diagnosed pulmonary embolism in the
right infrahilar region; this was treated with
anticoagulants. In 1999 he had a subdural
hematoma, which was treated by craniotomy
and evacuation. Laboratory tests, renal biop-
sies, and clinical evaluations by rheumatolo-
gists at the Mayo Clinic, the University of
New Mexico, and in San Francisco, California,
confirmed the diagnoses of microscopic
polyangiitis, systemic necrotizing vasculitis,
leukocytoclastic vasculitis, and glomerulo-
nephritis with positive antineutrophil cytoplas-
mic antibodies (ANCA) perinuclear pattern
(pANCA) and negative cytoplasmic pattern
(cANCA).
In 1999, the patient’s joint pain became
severe again, and he was placed on prednisone
and methotrexate until remission. His kidney
function remained stable until 2002 (Table 1)
when he was again placed on prednisone and
cyclophosphamide. 
Spirometry of the patient in 1992 showed
a reduction in lung function (mixed obstruc-
tive/restrictive pattern with moderate obstruc-
tion; Table1). A high resolution computerized
tomography (CT) scan of the chest in 2001
showed fine linear markings at the bases
extending to the pleural surface, with thick-
ened interlobular septa. 
In 2000, the Former LANL Worker
Program screened the patient for health
effects related to beryllium, lead, radiation,
and noise exposure. Test results indicated no
lung disease related to beryllium exposure and
negative beryllium sensitivity, renal insuffi-
ciency (chronic renal failure) not related to
lead exposure but as a result of vasculitis, and
sensorineural hearing loss related to noise
exposure.
The patient had no family history of vas-
culitides or rheumatologic disorders. He had
smoked cigarettes (36 pack-year history) but
quit smoking in 1979. 
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Work in Department of Energy (DOE) facilities has exposed workers to multiple toxic agents
leading to acute and chronic diseases. Many exposures were common to numerous work sites.
Exposure to crystalline silica was primarily restricted to a few facilities. I present the case of a
63-year-old male who worked in DOE facilities for 30 years as a weapons testing technician. In
addition to silica, other workplace exposures included beryllium, various solvents and heavy met-
als, depleted uranium, and ionizing radiation. In 1989 a painful macular skin lesion was biopsied
and diagnosed as leukocytoclastic vasculitis. By 1992 he developed gross hematuria and dyspnea.
Blood laboratory results revealed a serum creatinine concentration of 2.1 mg/dL, ethrythrocyte
sedimentation rate of 61 mm/hr, negative cANCA (antineutrophil cytoplasmic antibody cyto-
plasmic pattern), positive pANCA (ANCA perinuclear pattern), and antiglomerular basement
membrane negative. Renal biopsy showed proliferative (crescentric) and necrotizing glomeru-
lonephritis. The patient’s diagnoses included microscopic polyangiitis, systemic necrotizing vas-
culitis, leukocytoclastic vasculitis, and glomerulonephritis. Environmental triggers are thought to
play a role in the development of an idiopathic expression of systemic autoimmune disease.
Crystalline silica exposure has been linked to rheumatoid arthritis, scleroderma, systemic lupus
erythematosus, rapidly progressive glomerulonephritis and some of the small vessel vasculitides.
DOE workers are currently able to apply for compensation under the federal Energy Employees
Occupational Illness Compensation Program (EEOICP). However, the only diseases covered by
EEOICP are cancers related to radiation exposure, chronic beryllium disease, and chronic silico-
sis. Key words: crystalline silica, Department of Energy workers, Energy Employees Occupational
Illness Compensation Program, Nevada test site, systemic vasculitis. Environ Health Perspect
111:1933–1938 (2003). doi:10.1289/ehp.6400 available via http://dx.doi.org/ [Online 6 October
2003]
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Environmental Medicine Grand RoundsFrom 1953 to 1959, the patient worked as
a sonar operator and electronics technician in
the Navy on a destroyer and a submarine. He
worked in areas with asbestos-covered pipes
but no friable asbestos. From 1959 to 1961, he
worked as a junior engineer at NASA, where
his work involved testing reentry vehicles in a
wind tunnel. The tunnel walls were ﬁnished,
so he had no dust exposure.
In his job as a weapons testing technician
and apparatus operator at the University of
California, Lawrence Livermore National
Laboratory (LLNL; Livermore, CA) from
1961 to 1966, the patient gathered data and
cleaned areas after weapons explosions. He
was in an underground bunker about 100 ft
from testing sites during explosions. Testing
was done every other day for 5 years. The
patient was provided protective clothing,
gloves, and a respirator. He was unable to
wear the respirator consistently because he
took the respirator off to talk; therefore, the
patient received a significant amount of res-
pirable dust exposure contaminated with
beryllium and depleted uranium.
From 1966 to 1971, the patient worked as
an assistant analyst for a Los Alamos National
Laboratory (LANL) contractor; he worked in
an office doing mostly computer work and
received no signiﬁcant exposures. He worked
as a technician for LANL from 1971 until he
retired in 1991. His work involved ﬁeld data
collections after explosions. Exposures at the
test sites included dust, noise, depleted ura-
nium, and ionizing radiation. The patient did
not work directly with lead or beryllium, but
he may have been exposed to small amounts
of these elements during detonation of test
shots. He worked in buildings with asbestos-
covered pipes but reported no direct work
with asbestos or exposure to asbestos dust. He
was not enrolled in a lead or asbestos monitor-
ing program. Exposure to solvents (i.e., ace-
tone, carbon tetrachloride, methylethyl
ketone), epoxies, and nitric acid fumes were
intermittent and brief during those years, and
he reported no acute symptoms while working
with chemicals. 
From 1983 to 1984 the patient was
assigned by LANL to work in oil shale mines
in Colorado. The mining operation was an in
situ perfusion operation to extract oil. His
underground job was to test and measure
explosions, instrumentation, and the structure
of the mines. During this period he drilled
holes, installed gauges, set charges, and gath-
ered information about the tests. He worked in
dusty conditions; he was given a dust mask but
wore it only periodically. 
From 1987 to 1991 the patient was
assigned by LANL to work at the Nevada Test
Site (NTS) underground (Figure 1). He
worked in Area 25, an abandoned silver mine
(drift tunnel) under construction, where there
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Table 1. Laboratory and spirometry test results.
June 1992 August 1992a 2000b 2002c
Hemoglobin (g/dL) 11.0 13.1 15.8 14.8
Ethrythrocyte sedimentation rate (mm/hr) 61 10
Blood urea nitrogen (mg/dL) 25 46
Creatinine (mg/dL) 2.1 1.7 1.8 4.2
cANCA Negative Negative
pANCA Positive Negative Positive
Anti-myeloperoxidase Positive
Anti-proteinase 3 Negative
Rheumatoid factor; ANA; cryoglobulins;  Negative 
cryoﬁbrinogen; hepatitis A, B, and C;
angioconverting enzyme;
immunoelectrophoresis; 
antiglomerular basement membrane 
antibodies
Urine protein (mg/24hr) 1,226 6,443
Urinalysis Protein 100 mg/dL Protein 100 mg/dL
11–20 RBCs/hpf No RBCs
Spirometry
FVC (L) (% predicted) 3.71 3.11
FEV1 (L) (%predicted) 2.40 1.95
FEV1/FVC (%) 64.7 63
Abbreviations: ANA, antinuclear antibodies; FEV1, forced expiratory volume in 1 sec; FVC, forced vital capacity; hpf, high-
power ﬁeld (microscopy); RBCs, red blood cells; RF, rheumatoid factor. 
aTreated with prednisone 60 mg and cyclophosamide 100 mg, both every day; weaned off slowly after remission. bTreated
with prednisone 10 mg every day and methotrexate 7.5 mg weekly; weaned off slowly after remission. cTreated with pred-
nisone 10 mg and cyclophosamide 150 mg, both every day.
Figure 1. Nevada Test Site tunnel. Map reproduced from DOE Nevada (2003). 
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St. Georgewas constant drilling and high levels of dust
for ≥ 8 hr/day for 4 months. Respiratory pro-
tection consisted of a dust mask, which he
often had to take off to talk. Until retirement,
the patient worked underground in Area 3, a
shaft tunnel, 0.25 mile below the surface; in
this job—setting up instruments to measure
data during explosions—he received moderate
dust exposure.
Discussion
The vasculitides are a group of diseases charac-
terized by inflammatory cell infiltration and
necrosis of blood vessel walls (Watts and Scott
1997). The classification (Langford 2003;
Mansi et al. 2002) and description of the vas-
culitides are presented in Table 2. The epi-
demiologic study of systemic vasculitides has
been difﬁcult because they are all rare condi-
tions. The annual incidence of systemic vas-
culitides in the United Kingdom has been
estimated to be 36.6/million (with the exclu-
sion of giant cell arteritis and cutaneous vas-
culitis) (Watts and Scott 1997). Specific
vasculitides are more rare than the systemic
vasculitides. In a study conducted in the
United Kingdom from 1988 to 1994, the
incidence of microscopic polyangiitis was
3.6/million (Watts and Scott 1997). There is
some indication that there are geographical
and ethnic differences in the occurrence of
vasculitides. Wegener’s granulomatosis and
giant cell arteritis are extremely rare in India
and Japan, but Takayasu arteritis is common.
The opposite seems to be true in northern
Europe. Wegener’s granulomatosis is common
and polyarteritis nodosa is rare in northern
Europe, but in southern Europe Wegener’s
granulomatosis is rare and polyarteritis nodosa
is common.
Vasculitides can be caused by an infec-
tion of the blood vessel wall (bacterial or
viral) or an immune response. Of interest are
the vasculitides associated with autoimmune
diseases such as lupus, rheumatoid arthritis,
scleroderma, and Wegener’s granulomatosis.
There are studies that explain the influence
of multiple complex genetic factors on the
development of autoimmunity and specific
autoimmune diseases (Theofilopoulos and
Kono 1998). Environmental triggers are
thought to play a role in the development of
an idiopathic expression of systemic auto-
immune diseases (Mayes 1999; Powell et al.
1999). Exogenous sex hormones (speciﬁcally
estrogen), pharmaceutical agents (i.e. penicil-
lamine, procainamide, bleomycin) silica,
organic solvents (i.e., vinyl chloride, trichloro-
ethylene, epoxy resins), herbicides, pesticides,
mercury, mercuric chloride, iodine, aromatic
amines, and hydrazine have been linked to
the development of systemic autoimmune
diseases (D’Cruz 2000; Gonzalez-Gay and
Garcia-Porrua 2001; Mayes 1999; Powell
et al. 1999; Smith and Germolec 1999).
Speciﬁcally, estrogen has been linked with the
risk of developing systemic lupus, sclero-
derma, and Raynaud disease (Mayes 1999);
solvents linked with systemic sclerosis and
scleroderma (Mayes 1999); mercuric chloride
linked with immune complex glomeru-
lonephritis (Mayes 1999; Powell et al. 1999);
and crystalline silica linked with rheumatoid
arthritis, systemic sclerosis, systemic lupus,
glomerulonephritis, and small-vessel vasculi-
tides (Koeger et al. 1995; Mayes 1999; Parks
et al. 1999; Powell et al. 1999; Steenland and
Goldsmith 1995). 
Small vessel vasculitides have a common
pathology of focal necrotizing lesions in the
lungs causing alveolar hemorrhage, in the
glomeruli of the kidney causing renal failure,
and in the dermis causing a purpuric rash or
ulcerations on the skin (Kamesh et al. 2002).
The most common primary small-vessel vas-
culitis that occurs in adults is associated with
ANCA (Mansi et al. 2002). ANCA are speciﬁc
antibodies for antigens in cytoplasmic granules
of neutrophils and monocyte lysosomes, have
their direct effects against proteinase 3 or
myeloperoxidase, and can be detected with
direct immunofluorescence microscopically
(Booth et al. 2003; Mansi et al. 2002). ANCA
directed against proteinase 3 has a cytoplasmic
immunofluorescence pattern and is noted as
cANCA. ANCA directed against myeloperoxi-
dase has a perinuclear immunofluorescence
pattern and is termed pANCA (Langford
2003). cANCA is positive in 75–90% of
Wegener granulomatosis cases, and pANCA
positivity is most commonly seen in micro-
scopic polyangiitis (Mansi et al. 2002). Fever,
myalgia, anorexia, weight loss, malaise, and
night sweats are common early symptoms of
vasculitis. Microscopic polyangiitis usually has
renal involvement, and patients present with
hematuria, proteinuria, and red cell casts and
can have rapid renal failure. Pulmonary hemor-
rhage can occur in microscopic polyangiitis,
but unlike Wegener granulomatosis, upper air-
way involvement is rare. Untreated ANCA-
positive vasculitis has a very poor prognosis
with up to 90% mortality in 2 years (Kamesh
et al. 2002). Current standard treatment is
based on cyclophosamide and high-dose
corticosteroids (Mansi et al. 2002). The goal of
therapy is to induce remission, maintain remis-
sion, and treat relapses. Treatment-related
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Table 2. Classiﬁcation of systemic vasculitis.
Class Name Pathophysiology Characteristics
Large-vessel Giant cell arteritis Granulomatous inﬂammation Most common over 50 
vasculitis  affects aorta and major  years of age; frequency 
branches, carotid, cranial,  increases with aging; 
and temporal arteries associated with polymyalgia 
rheumatica
Takayasu arteritis  Granulomatous Occurs in patients under
inﬂammation of aorta  50 years of age; associated 
and major branches, with connective tissue, 
pulmonary and autoimmune, endocrine,
coronary arteries inﬂammatory bowel, and
sarcoidosis
Medium-vessel Polyarteritis nodosa Necrotizing inﬂammation  Two times more common 
vasculitis of medium size or small  in men, typically during 
vessels the 40s and 50s; without 
glomerulonephritis or 
vasculitis in small vessels; 
ANCA positive is rare
Kawasaki disease Vasculitis of coronary  Occurs usually in children;
arteries; aorta and veins  associated with 
may be involved mucocutaneous lymph
node syndrome; potential
aneurism formation
Small-vessel Henoch-Schonlein Necrotizing vasculitis;  Most common vasculitis
vasculitis purpura IgA-dominant immune in children and infrequent in
deposits in walls of adults; involves skin, gut, 
small vessels and renal and glomeruli; associated
glomeruli with arthralgias or arthritis
Wegener Granulomatous Equal in men and women;
granulomatosis inﬂammation involving  occurs in any age; necrotizing
upper and lower respiratory  glomerulonephritis common;
tract and necrotizing  cANCA positive
vasculitis affecting small 
to medium vessels
Microscopic Necrotizing arteritis, few  Cardinal features include
polyangiitis  or no immune deposits;  glomerulonephritis,
affects small vessels pulmonary hemorrhage,
mononeuritis multiplex, and
fever; pANCA positive
Adapted from Langford (2003) and Mansi et al. (2002).complications including steroid-induced dia-
betes, bladder and lymphoproliferative malig-
nancy, and infertility can occur in more than
50% of treated patients (Kamesh et al. 2002).
Alternate treatment includes methotrexate, aza-
thioprine, trimethoprim-sulfamethoxazole,
plasma exchange, cyclosporine, intravenous
immunoglobulin, and monoclonal antibodies
(Kamesh et al. 2002; Mansi et al. 2002).
Silica (silicon dioxide), one of the occupa-
tional and environmental exposures linked to
autoimmune diseases, is formed from the two
most abundant elements in the earth’s crust,
oxygen and silicon (U.S. Department of the
Interior 2003). SiO2 occurs in a non-crystalline
(amorphous) or a crystalline form. Crystalline
silica is found in seven forms (polymorphisms)
[National Institute for Occupational Safety
and Health (NIOSH) 2002; U.S. Department
of the Interior 2003], of which quartz, cristo-
balite, and tridymite are the most common.
The quartz form is an abundant component of
soil and rock; the term is often used to refer to
crystalline silica. It is when the crystalline sil-
ica-containing rock and sand is used or
processed (i.e., mining, quarrying, drilling,
sand blasting, tunneling operations) that
workers can be exposed to airborne dust levels
of respirable crystalline silica that can cause
respiratory diseases. Occupational exposure to
respirable crystalline silica is associated with a
number of respiratory diseases, including sili-
cosis (acute, accelerated, and chronic), progres-
sive pulmonary fibrosis, chronic obstructive
pulmonary disease (e.g., chronic bronchitis,
emphysema), and lung cancer, and places
workers with silicosis at higher risk for tubercu-
losis (American Thoracic Society Committee
of the Scientiﬁc Assembly on Environmental
and Occupational Health 1997; NIOSH
2002).
The patient worked from 1983 to 1984 in
the two oil shale mines (Exxon and Union) in
existence in the 1980s in Garfield County,
Colorado. The geologic underground rock
formation in the area is oil shale and marl-
stone. The dominant matrix minerals in oil
shale and marlstone include silicates. The
above-ground rock formation is sandstone and
also contains high silica content (Chenoweth
W. Personal communication).
Pepper et al. (1998) studied former workers
of the NTS and tried to quantify silica exposure
rates. In the Phase 1 report of exposures from
the NTS, Pepper et al. (1998) noted that the
underground environment and the work of
drilling, blasting, and mucking provided an
essentially uniform dust exposure to all workers
(Figure 2). The tunnels are geologically made
of soft volcanic tuff. As reported by Pepper et
al. (1998), a 1959–1971 U.S. Geologic
Survey measured core samples and found a
70% silica concentration weighted average in
1959, and 10–40% cristobalite/crystalline 
silica concentration weighted average in 1971.
The use of silica-containing grout compound
also added to the respirable silica contamina-
tion of the ambient air (Pepper et al. 1998) at
the NTS. The silica-containing grout was
used in the areas around the line-of-sight and
the bypass drift and along the tunnels to per-
mit the containment of explosions, moderate
potential geological stress, and plug any frac-
tures that may have been formed after an
explosion. Pepper et al. (1998) reported that
area sampling of respirable dust conducted in
1974 as part of the industrial hygiene pro-
gram at the NTS showed total dust concen-
trations of 2–543 mg/m3 and the percentage
of free silica of 0–62%. The permissible expo-
sure levels to respirable quartz as established
by the Occupational Safety and Health
Administration (OSHA 2003) for an 8-hr
time-waited average are determined as follows:
10 mg/m3 ÷ (percentage of silica + 2).
Industrial hygiene records available from the
NTS show that exposures were probably
above levels mandated by OSHA (Pepper L.
Personal communication). 
Respiratory complications from crystalline
silica exposures have been known for centuries,
but the link of silica exposure and autoimmune
disease has been more recent. In the 1950s,
Caplan (1953) ﬁrst described unusual radio-
logic changes in the lungs of Welsh coal miners
who had pneumoconiosis. In a subsequent
study of these miners, Miall et al. (1953) found
that the rheumatoid lesions in the lung were
predictive for rheumatoid arthritis (subse-
quently called Caplan’s syndrome). Since that
time many studies have examined the link
between crystalline silica exposure and develop-
ment of autoimmune diseases (Parks et al.
1999). Among the systemic autoimmune dis-
eases, occupational exposure to crystalline silica
exposure has been linked to rheumatoid arthri-
tis, scleroderma, systemic lupus erythematosus,
and some of the small vessel vasculitides
(Koeger et al. 1995; Parks et al. 1999). 
Crystalline silica particles are ingested by
alveolar macrophages and result in inﬂamma-
tion and activation of ﬁbroblasts (Parks et al.
1999). The digested crystalline silica destroys
the macrophages, and the crystalline silica is
again digested by new macrophages. This
repeated process leads to chronic immune
activity and ﬁbrosis. Studies have shown that
crystalline silica can be mobilized from the
lungs to other organs, including lymph nodes,
spleen, and kidney (Parks et al. 1999). Silicosis
and mineral dust pneumoconiosis have been
linked to an increase in autoantibodies,
immune complexes, and excess production of
immunoglobulins, even in the absence of a
specific autoimmune disease (Jones et al.
1976; Lippmann et al. 1973). Many of the
cases of autoimmune disease were ﬁrst discov-
ered during screening of silica-exposed work-
ers or workers who were being treated for
silicosis. It was not clear in these cases whether
the silicosis was a pathologic process that may
predispose some individuals to develop
autoimmune disease or whether the opposite
was true, that the autoimmune disease may
Environmental Medicine | Mulloy
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Figure 2. Nevada Test Site. Photograph reproduced from DOE Nevada (2003).predispose some individuals to develop silicosis
in the lung (Parks et al. 1999).
The mechanism of crystalline silica in the
development of autoimmune diseases may be a
result of the adjuvant effect on antibody pro-
duction (Parks et al. 1999). (An adjuvant is a
substance that enhances an immune response
to an antigen.) The development of silicosis is
dose dependent, but no studies have deter-
mined a dose–response or threshold effect of
crystalline silica as an adjuvant. Genetic differ-
ences and susceptibility to autoimmune dis-
eases may vary the characteristics and extent of
the inflammation caused by silica exposure.
Crystalline silica can also cause cell death by
necrosis and apoptosis (an active process
involving gene regulation) (Nowack et al.
1998; Otsuki et al. 1998). Apoptosis is
enhanced by silica and at levels where an acute
toxicity is not detected. The sFas ligand, a type
II membrane protein that induces apoptosis, is
elevated in silicosis patients (Tomokuni et al.
1999). The elevation of sFas levels have been
reported in silicosis patients who have slight
shortness of breath, normal partial pressure of
carbon dioxide (Tomokuni et al. 1999), or
normal partial pressure of oxygen (Tomokuni
et al. 1997) and have been classiﬁed with slight
respiratory disorders. Tomokuni et al. (1997)
speculated that the severity of respiratory
involvement may not occur to the same degree
as the abnormalities and elevation of apoptosis-
related molecules in silicosis patients.
Tomokuni et al. (1999) found no signiﬁcant
correlation of duration of exposure to crys-
talline silica dust and the serum levels of sFas.
Host susceptibility may explain why all work-
ers exposed to silica do not develop auto-
immune disorders (Gregorini et al. 1997).
There is experimental and clinical evidence
that crystalline silica affects the immune
response. Gregorini et al. (1997) reported the
presence of increased rheumatoid factors and
antinuclear antibodies in 26–44% of patients
with silicosis. The most frequently reported
autoimmune diseases among crystalline-silica
exposed workers are scleroderma, rheumatoid
arthritis, systemic lupus erythematosus, auto-
immune hemolytic anemia, and dermatomyosi-
tis or dermatopolymyositis (NIOSH 2002;
Steenland and Goldsmith 1995; Tervaert et al.
1998). A statistically significant association
between crystalline silica exposure and several
renal diseases has been reported in epidemio-
logic studies (NIOSH 2002). Steenland et al.
(2001) reported an increasing standardized rate
ratio for acute and chronic renal disease with
increasing cumulative crystalline silica exposure
and an excess of end-stage renal disease inci-
dence (highest for glomerulonephritis). The
reported cases of glomerulonephritis in patients
with crystalline silica exposure show rapid pro-
gression and are associated with positive anti-
neutrophil cytoplasmic antibodies (ANCA)
with or without systemic vasculitis, such as
Wegener granulomatosis or microscopic
polyangiitis (Gregorini et al. 1993, 1997).
pANCA is strongly associated with micro-
scopic polyangiitis and rapidly progressive
glomerulonephritis (RPGN) (Danning et al.
1998). In a recent study (Gregorini et al.
1997), crystalline silica–exposed patients with
positive ANCA showed mainly a pANCA pat-
tern. Not all silica-exposed patients with
pANCA-positive RPGN reported by Gregorini
et al. (1993) had pulmonary silicosis. Gregorini
et al. (1997) reported immune abnormalities in
patients with silicosis and in silica-exposed
patients with no evidence of lung disease.
The intensity of exposure to silica dust
may be more important than cumulative
exposure or duration in the development of
autoimmune diseases (Martin et al. 1999;
Sluis-Cremer et al. 1986, 1985). In a study of
silica-exposed gold miners, Calvert et al.
(1997) investigated end-stage renal disease
(ESRD) and exposures. They suggested that
crystalline silica exposure was most strongly
associated with ESRD (especially ESRD
caused by glomerulonephritis) and that the
median exposure of the cohort was below the
OSHA permissible exposures levels (indicat-
ing a lower level of exposure needed to start
the disease process).
Effects of silica are thought to be either
immune-complex mediated or a result of
direct toxic effects of the silica on the
glomeruli. Long latency periods (15–25 years)
have been reported between first silica expo-
sure and the development of autoimmune dis-
eases. However, in a 1987 study of granite
workers, Klockars et al. (1987) documented
individuals who developed autoimmune dis-
ease in a shorter period of time. The authors
published results of a followup of 35 workers
exposed to silica who had developed rheuma-
toid arthritis. Of the workers, 13 had ≤ 5 years
of exposure before the onset of rheumatoid
arthritis. For 7 of the workers, latency ranged
from 1 to 12 years. This study was also inter-
esting in that 20 of the 35 miners had normal
chest X rays at the time of the onset of
rheumatoid arthritis. 
The issue of latency was also addressed by
Parks et al. (2002), who evaluated occupa-
tional exposure to silica and the risk of sys-
temic lupus erythematosus (SLE). In this
population-based, case–control study, the
authors observed an association between silica
and SLE, with medium or high-level silica
exposures found in individuals working in
farming or trades. The analysis revealed no
predominant time window of exposure that
accounted for the association observed
between silica and SLE. 
Irregular opacities in the bases of the
lungs, with pleural thickening, that were
detected by the case patient’s chest CT scan
are consistent with asbestos-related lung disease
(Churg 1998; Rom 1998), silicosis and mixed-
dust pneumoconiosis (Honma and Chiyotani
1993; Shida et al. 1996), idiopathic pul-
monary ﬁbrosis, and smoking tobacco (Dick
et al. 1992). Although silicosis is classically
described as rounded opacities in the upper
lobes, some studies and reviews of the litera-
ture describe a less classical ﬁnding of irregular
opacities in the lower lobes (Dick et al. 1992;
Gibbs and Wagner 1998). Honma and
Chiyotani (1993) described diffuse interstitial
ﬁbrosis (DIF) among workers with a variety of
occupations (rock driller, stone mason, metal
miner, tunneler, construction worker). The
cases were diagnosed pathologically as silicosis
(142 cases) or mixed dust pneumoconiosis
(91 cases); the diffuse interstitial ﬁbrosis was
predominantly in the lower lobes and thicken-
ing and adhesion of the pleura covering the
DIF was seen in 40.6% of the cases. Two cases
were associated with collagen disease, one case
was associated with systemic sclerosis, and one
was associated with rheumatoid arthritis. In
addition, no signiﬁcant correlation was found
between the occurrence of DIF and smoking
history (Honma and Chiyotani 1993).
The Energy Employees Occupational
Illness Compensation Program Act (EEOICPA;
DOE 2003) was passed by the U.S. Congress
in October 2000 and went into effect 31 July
2001. The compensation program provides for
workers or survivors who have become ill or
who have died as a result of exposure to beryl-
lium, silica, or ionizing radiation while work-
ing for the DOE and its contractors or
subcontractors in the nuclear weapons indus-
try. The diseases covered by EEOICPA include
cancer caused by radiation, chronic beryllium
lung disease, and chronic silicosis. Workers
with beryllium sensitivity are eligible for med-
ical monitoring. For those diseases related to
workplace exposures not covered under
EEOICPA, Congress has directed the DOE to
help workers ﬁle state workers’ compensation
claims. A system including a three-physician
panel has been established to review all medical
claims. If the panel ﬁnds that a medical condi-
tion not covered under EEOICPA is related to
workplace exposures at a DOE facility, the
applicant can include the panel report with the
claim for state workers’ compensation.
Conclusion
I have presented the case of a DOE worker
with several years of high-intensity exposure to
respirable crystalline silica in his workplace. The
patient developed pANCA-positive systemic
vasculitides (microscopic polyangiitis) with
progressive necrotizing glomerulonephritis.
Most of the studies on the relationship of silica
exposure and the development of systemic vas-
culitides have been conducted among patients
with silicosis, but there is sufﬁcient mention in
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develop independently of silicosis in patients
with crystalline silica exposure. Epidemiologic
studies link solvent exposure to an increased
risk of systemic sclerosis but not systemic
pANCA-positive vasculitis. The patient’s
exposure to solvents has not contributed to the
development of his systemic vasculitis. In
addition, the patient’s other workplace expo-
sures—beryllium, asbestos, lead, and ionizing
radiation—are not known causes of systemic
vasculitis. On the chest CT scan, the patient
did not have the more common abnormality
of rounded opacities in the upper lobes, but
instead had a linear pattern of interstitial lung
ﬁbrosis with pleural thickening. This pattern
of pulmonary ﬁbrosis has a larger number of
potential causes and risk factors. The literature
supports the possibility that his chest CT scan
ﬁndings of lower lobe interstitial ﬁbrosis may
be attributed to the silica exposure.
DOE workers are currently able to apply
for compensation under the federal EEOICP.
As of 29 August 2003, 18,823 workers nation-
wide had applied for compensation under
EEOICP (DOE Office of Worker Advocacy
2003). Of these applications, 1,077 case claims
have been completed; 928 claims have been
declared ineligible; 75 claims have been with-
drawn by the applicant; 2,806 claims are being
developed; 374 cases have been developed and
are awaiting final review by the applicant;
14,434 cases are awaiting development; and
132 claims are currently in the physician panel
process. Of the claims reviewed by the physi-
cian’s panel the panel returned 45 positive
findings and 29 negative findings. The only
diseases covered by EEOICP are cancers
related to radiation exposure, chronic beryl-
lium disease, and chronic silicosis. All other
diseases are to be covered under state Workers’
Compensation systems. The differences in each
state’s workers’ compensation law and the
resistance of employers have made compensa-
tion difﬁcult to obtain for many workers with
serious diseases. Currently, many workers must
rely on private insurance, Medicare, or public
or charity health plans to cover their medical
expenses. Federal legislation should be devel-
oped to cover all diseases related to workplace
exposures in DOE workers.
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